InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595. PMID: 38838676; PMCID: PMC11228653.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432. PMID: 38629963; PMCID: PMC11147689.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Schaverien MV, Singh P, Smith BD, Qiao W, Akay CL, Bloom ES, Chavez-MacGregor M, Chu CK, Clemens MW, Colen JS, Ehlers RA, Hwang RF, Joyner MM, Largo RD, Mericli AF, Mitchell MP, Shuck JW, Tamirisa N, Tripathy D, Villa MT, Woodward WA, Zacharia R, Kuerer HM, Hoffman KE. Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical Trial. JAMA Netw Open. 2024 Apr 01; 7(4):e245217. PMID: 38578640; PMCID: PMC10998161.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Mouabbi JA, Qaio W, Shen Y, Raghavendra AS, Tripathy D, Layman RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist. 2024 Mar 04; 29(3):213-218. PMID: 38070191; PMCID: PMC10911914.
      Citations:    Fields:    Translation:Humans
    5. Adesoye T, Tripathy D, Hunt KK, Keyomarsi K. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics. Cancers (Basel). 2024 Jan 24; 16(3). PMID: 38339245; PMCID: PMC10854592.
    6. Kumar D, Gurrapu S, Wang Y, Bae SY, Pandey PR, Chen H, Mondal J, Han H, Wu CJ, Karaiskos S, Yang F, Sahin A, Wistuba II, Gao J, Tripathy D, Gao H, Izar B, Giancotti FG. LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells. Nat Cancer. 2024 Feb; 5(2):262-282. PMID: 38195932.
      Citations: 1     Fields:    Translation:AnimalsCells
    7. Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2349646. PMID: 38153734; PMCID: PMC10755617.
      Citations:    Fields:    Translation:HumansCells
    8. Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250. PMID: 37573674; PMCID: PMC10529602.
      Citations:    Fields:    Translation:Humans
    9. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res. 2023 06 06; 25(1):62. PMID: 37280713; PMCID: PMC10245436.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    10. Mouabbi JA, Singareeka Raghavendra A, Bassett RL, Hassan A, Tripathy D, Layman RM. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open. 2023 05 01; 6(5):e2313017. PMID: 37166793; PMCID: PMC10176119.
      Citations: 3     Fields:    Translation:Humans
    11. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213. PMID: 37016732.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq. 2023 Feb 14. PMID: 36824840; PMCID: PMC9949251.
    13. Kaler A, McClosky V, Raghavendra AS, Tripathy D. Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction. Clin J Oncol Nurs. 2022 06 01; 26(3):308-312. PMID: 35604739.
    14. Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022 Jun; 193(2):253-264. PMID: 35347549.
      Citations: 1     Fields:    Translation:Humans
    15. Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, Kuhn P, Hicks JB, Welter L, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy D, Pusztai L, Hortobagyi GN. A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. Clin Cancer Res. 2022 02 15; 28(4):611-617. PMID: 34844978; PMCID: PMC9782801.
      Citations:    Fields:    Translation:Humans
    16. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 12 16; 385(25):2336-2347. PMID: 34914339; PMCID: PMC9096864.
      Citations: 33     Fields:    Translation:Humans
    17. Ly S, Anand V, El-Dana F, Nguyen K, Cai Y, Cai S, Piwnica-Worms H, Tripathy D, Sahin AA, Andreeff M, Battula VL. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 03; 9(3). PMID: 33722905; PMCID: PMC7970220.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    18. Zhao H, Shen J, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH. Validation of plasma metabolites associated with breast cancer risk among Mexican Americans. Cancer Epidemiol. 2020 12; 69:101826. PMID: 33010726; PMCID: PMC7710579.
      Citations:    Fields:    Translation:Humans
    19. I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362. PMID: 32701140; PMCID: PMC7378873.
      Citations: 22     Fields:    Translation:Humans
    20. Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone?receptor-positive advanced breast cancer. Future Oncol. 2020 Nov; 16(31):2475-2485. PMID: 32787449.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    21. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020 04 01; 6(4):505-511. PMID: 31917424; PMCID: PMC6990911.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    22. Jeong YJ, Raghavendra AS, Mack WJ, Tripathy D, Yamashita MW, Sheth PA, Hovanessian Larsen L, Russell CA, Wecsler J, MacDonald H, Sener SF, Lang JE. Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers. J Surg Oncol. 2020 Mar; 121(4):589-598. PMID: 31984517; PMCID: PMC7032991.
      Citations:    Fields:    Translation:Humans
    23. Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH. Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat. 2019 08; 176(3):697. PMID: 31154579.
      Citations:    Fields:    
    24. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5). PMID: 31137625; PMCID: PMC6562947.
      Citations: 42     
    25. Whisenant MS, Strunk FA, Tripathy D, Williams LA. What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer. Support Care Cancer. 2019 Dec; 27(12):4639-4647. PMID: 30937601.
      Citations: 1     Fields:    Translation:Humans
    26. Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH. Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat. 2019 Aug; 176(3):687-696. PMID: 30771047; PMCID: PMC6588417.
      Citations: 8     Fields:    Translation:Humans
    27. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069. PMID: 32031889; PMCID: PMC7106976.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    28. Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM. Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412. PMID: 30518672; PMCID: PMC7357548.
      Citations: 5     Fields:    Translation:HumansCells
    29. Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D. Overall survival in older patients with cancer. BMJ Support Palliat Care. 2020 Mar; 10(1):25-35. PMID: 30244203.
      Citations: 6     Fields:    Translation:Humans
    30. Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol. 2018 Aug; 35:69-76. PMID: 29843069.
      Citations: 3     Fields:    Translation:Humans
    31. Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin RE. Neurocognitive deficits in older patients with cancer. J Geriatr Oncol. 2018 09; 9(5):482-487. PMID: 29530493.
      Citations: 4     Fields:    Translation:Humans
    32. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget. 2018 Jan 23; 9(6):6872-6882. PMID: 29467936; PMCID: PMC5805522.
      Citations: 3     Fields:    
    33. Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568. PMID: 29197959.
      Citations: 3     Fields:    Translation:Humans
    34. Tripathy D, Bardia A, Sellers WR. Mechanism of Action and Clinical Impact of Ribociclib-Response. Clin Cancer Res. 2017 09 15; 23(18):5658. PMID: 28916619.
      Citations: 1     Fields:    Translation:Humans
    35. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 01; 3(9):1266-1273. PMID: 28301631.
      Citations: 76     Fields:    Translation:HumansCells
    36. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662. PMID: 28928852; PMCID: PMC5604195.
      Citations: 14     
    37. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400; PMCID: PMC5559961.
      Citations: 6     
    38. Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017 07 01; 23(13):3251-3262. PMID: 28351928; PMCID: PMC5727901.
      Citations: 62     Fields:    Translation:HumansCells
    39. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346; PMCID: PMC5259558.
      Citations: 117     Fields:    Translation:HumansCTClinical Trials
    40. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347; PMCID: PMC5259561.
      Citations: 177     Fields:    Translation:HumansCTClinical Trials
    41. Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9. PMID: 27138575; PMCID: PMC5012690.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    42. Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76. PMID: 26896384.
      Citations: 10     Fields:    Translation:Humans
    43. Silberman H, Sheth PA, Parisky YR, Hovanessian-Larsen LJ, Sheth S, Tripathy D. Modified Bi-Rads Scoring of Breast Imaging Findings Improves Clinical Judgment. Breast J. 2015 Nov-Dec; 21(6):642-50. PMID: 26411901.
      Citations:    Fields:    Translation:Humans
    44. Tripathy D. The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. BMC Med. 2015 Sep 23; 13:223. PMID: 26394747; PMCID: PMC4580146.
      Citations: 1     Fields:    Translation:Humans
    45. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23. PMID: 26272743.
      Citations: 8     Fields:    Translation:Humans
    46. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. J Cancer. 2015; 6(7):610-5. PMID: 26078790; PMCID: PMC4466409.
      Citations: 5     
    47. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45. PMID: 25987700; PMCID: PMC5098846.
      Citations: 43     Fields:    Translation:Humans
    48. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043.
      Citations: 40     Fields:    Translation:Humans
    49. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14. PMID: 25605252; PMCID: PMC4413604.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    50. Greenlee H, Zick SM, Rosenthal D, Cohen L, Cassileth B, Tripathy D. Integrative oncology - strong science is needed for better patient care. Nat Rev Cancer. 2015 Mar; 15(3):165. PMID: 25693833.
      Citations:    Fields:    Translation:Humans
    51. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31. PMID: 25432738; PMCID: PMC4698170.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    52. Lang JE, Wecsler JS, Press MF, Tripathy D. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015 Jan; 111(1):81-90. PMID: 25091830.
      Citations: 16     Fields:    Translation:Humans
    53. Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64. PMID: 24743708; PMCID: PMC4037822.
      Citations: 20     Fields:    Translation:Humans
    54. Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):725-34. PMID: 24706168; PMCID: PMC4031392.
      Citations: 34     Fields:    Translation:Humans
    55. Dieli-Conwright CM, Mortimer JE, Schroeder ET, Courneya K, Demark-Wahnefried W, Buchanan TA, Tripathy D, Bernstein L. Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. BMC Cancer. 2014 Apr 03; 14:238. PMID: 24708832; PMCID: PMC3985576.
      Citations: 29     Fields:    Translation:Humans
    56. Lee SC, Jain PA, Jethwa SC, Tripathy D, Yamashita MW. Radiologist's role in breast cancer staging: providing key information for clinicians. Radiographics. 2014 Mar-Apr; 34(2):330-42. PMID: 24617682.
      Citations: 15     Fields:    Translation:Humans
    57. Kim M, Agarwal S, Tripathy D. Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer. Curr Opin Obstet Gynecol. 2014 Feb; 26(1):27-33. PMID: 24335887.
      Citations: 3     Fields:    Translation:Humans
    58. Tripathy D, Durie BG, Mautner B, Ferenz KS, Moul JW. Awareness, concern, and communication between physicians and patients on bone health in cancer. Support Care Cancer. 2014 Jun; 22(6):1601-10. PMID: 24477326.
      Citations: 4     Fields:    Translation:Humans
    59. Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast. 2014 Feb; 23(1):2-9. PMID: 24176518.
      Citations: 14     Fields:    Translation:HumansCells
    60. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA. Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70. PMID: 24062208; PMCID: PMC3824350.
      Citations: 15     Fields:    Translation:Humans
    61. Baniwal SK, Chimge NO, Jordan VC, Tripathy D, Frenkel B. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One. 2014; 8(6):e62361. PMID: 23755096; PMCID: PMC3670933.
      Citations: 17     Fields:    Translation:HumansCells
    62. Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist. 2013; 18(5):501-10. PMID: 23652380; PMCID: PMC3662840.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    63. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. PMID: 23470967; PMCID: PMC4096560.
      Citations: 7     Fields:    Translation:Humans
    64. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      Citations: 4     Fields:    Translation:Humans
    65. Jiang L, Weatherall PT, McColl RW, Tripathy D, Mason RP. Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. J Magn Reson Imaging. 2013 May; 37(5):1083-92. PMID: 23124705.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    66. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012 Oct; 135(3):875-83. PMID: 22923238; PMCID: PMC3439611.
      Citations: 16     Fields:    Translation:Humans
    67. Perez EA, Burris HA, Mooberry S, Tripathy D. New treatment paradigms for optimizing survival in advanced and metastatic breast cancer. Clin Adv Hematol Oncol. 2012 Aug; 10(8 Suppl 13):1-14; quiz 15-6. PMID: 23072876.
      Citations:    Fields:    Translation:HumansCells
    68. Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer. J Med Internet Res. 2012 Jul 11; 14(4):e97. PMID: 22784878; PMCID: PMC3409596.
      Citations: 4     Fields:    Translation:Humans
    69. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. PMID: 22649152; PMCID: PMC3434983.
      Citations: 173     Fields:    Translation:Humans
    70. Tripathy D. Breast cancer quality care: what is at stake? Breast J. 2012 May-Jun; 18(3):201-2. PMID: 22583193.
      Citations:    Fields:    Translation:Humans
    71. Tripathy D. Using neoadjuvant therapy for breast cancer in clinical practice: when and how? Breast Cancer Res Treat. 2012 Apr; 132(3):775-7. PMID: 22438051.
      Citations:    Fields:    Translation:Humans
    72. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. PMID: 22198468; PMCID: PMC3332388.
      Citations: 169     Fields:    Translation:Humans
    73. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 2011; 13(6):R127. PMID: 22151997; PMCID: PMC3326569.
      Citations: 69     Fields:    Translation:HumansCells
    74. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res. 2012 Feb 01; 18(3):901-11. PMID: 22147940; PMCID: PMC3277803.
      Citations: 29     Fields:    Translation:HumansCells
    75. Tripathy D. PARP inhibitors: the story is still unfolding. Oncology (Williston Park). 2011 Oct; 25(11):1028, 1030. PMID: 22106553.
      Citations:    Fields:    Translation:Humans
    76. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9. PMID: 21796368; PMCID: PMC3975048.
      Citations: 10     Fields:    Translation:Humans
    77. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43. PMID: 21768129.
      Citations: 125     Fields:    Translation:Humans
    78. Langford DJ, Paul SM, Tripathy D, West C, Dodd MJ, Schumacher K, Miaskowski C. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain during participation in a psychoeducational intervention study to improve pain management. J Pain. 2011 Jun; 12(6):652-66. PMID: 21429811; PMCID: PMC3111875.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    79. Langford DJ, Tripathy D, Paul SM, West C, Dodd MJ, Schumacher K, Miaskowski C. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain. 2011 Apr; 12(4):495-507. PMID: 21310669; PMCID: PMC3073575.
      Citations: 11     Fields:    Translation:Humans
    80. Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer. Clin Breast Cancer. 2010 Dec 01; 10(6):421-39. PMID: 21147685.
      Citations: 2     Fields:    Translation:HumansCells
    81. Tripathy D. FDA and Avastin: crossroads in an era of targeted therapies. Oncology (Williston Park). 2010 Oct; 24(11):989-90. PMID: 21155445.
      Citations: 1     Fields:    Translation:Humans
    82. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb; 120(1):111-8. PMID: 20054647.
      Citations: 29     Fields:    Translation:HumansAnimalsCTClinical Trials
    83. Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D, Vicini FA, Whitworth PW, Willey SC. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg. 2009 Oct; 209(4):504-20. PMID: 19801324.
      Citations: 40     Fields:    Translation:HumansPHPublic Health
    84. Block KI, Gyllenhaal C, Tripathy D, Freels S, Mead MN, Block PB, Steinmann WC, Newman RA, Shoham J. Survival impact of integrative cancer care in advanced metastatic breast cancer. Breast J. 2009 Jul-Aug; 15(4):357-66. PMID: 19470134.
      Citations: 6     Fields:    Translation:Humans
    85. Tripathy D. Are we hitting the right combination for hormonally sensitive breast cancer? J Clin Oncol. 2009 Jun 01; 27(16):2580-2. PMID: 19380439.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    86. Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-7. PMID: 18501057.
      Citations: 2     Fields:    Translation:Humans
    87. Ranganathan A, Muneer S, Cunningham S, Shivakumar L, Tripathy D. Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007. Support Cancer Ther. 2007 May 01; 4(3):137-44. PMID: 18632479.
    88. Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007 Apr 18; (2):CD004921. PMID: 17443560; PMCID: PMC9028047.
      Citations: 34     Fields:    Translation:Humans
    89. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007 Apr; 33(4):462-72. PMID: 17397707.
      Citations: 25     Fields:    Translation:Humans
    90. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 2007 Apr; 12(4):375-89. PMID: 17470680.
      Citations: 11     Fields:    Translation:Humans
    91. Tripathy D. Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways. Nat Clin Pract Oncol. 2007 Apr; 4(4):220-1. PMID: 17342070.
      Citations: 2     Fields:    
    92. Miaskowski C, Dodd M, West C, Paul SM, Schumacher K, Tripathy D, Koo P. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain. 2007 May; 129(1-2):55-63. PMID: 17257753; PMCID: PMC1906700.
      Citations: 17     Fields:    Translation:Humans
    93. Villars P, Dodd M, West C, Koetters T, Paul SM, Schumacher K, Tripathy D, Koo P, Miaskowski C. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage. 2007 Jan; 33(1):67-77. PMID: 17196908; PMCID: PMC1839901.
      Citations: 12     Fields:    Translation:Humans
    94. Deng GE, Cassileth BR, Cohen L, Gubili J, Johnstone PA, Kumar N, Vickers A, Society for Integrative Oncology Executive Committee, Abrams D, Rosenthal D, Sagar S, Tripathy D. Integrative Oncology Practice Guidelines. J Soc Integr Oncol. 2007; 5(2):65-84. PMID: 17511932.
      Citations: 18     Fields:    Translation:Humans
    95. Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 2007 Sep; 105(1):17-28. PMID: 17111207.
      Citations: 30     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    96. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17361-5. PMID: 17079488; PMCID: PMC1838539.
      Citations: 56     Fields:    Translation:HumansCells
    97. Guo J, Zhou AW, Fu YC, Verma UN, Tripathy D, Frenkel EP, Becerra CR. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin. 2006 Oct; 27(10):1375-81. PMID: 17007746.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    98. Diel IJ, Tripathy D, Bergstrom B, Body JJ. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl). 2006 Jul; 15(3):299-302. PMID: 16882128.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    99. McLachlan SA, Cameron D, Murray R, Tripathy D, Bergstr?m B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clin Drug Investig. 2006; 26(1):43-8. PMID: 17163234.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    100. Silverstein MJ, Lagios MD, Recht A, Allred DC, Harms SE, Holland R, Holmes DR, Hughes LL, Jackman RJ, Julian TB, Kuerer HM, Mabry HC, McCready DR, McMasters KM, Page DL, Parker SH, Pass HA, Pegram M, Rubin E, Stavros AT, Tripathy D, Vicini F, Whitworth PW. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg. 2005 Oct; 201(4):586-97. PMID: 16183499.
      Citations: 24     Fields:    Translation:Humans
    101. Kwak YT, Li R, Becerra CR, Tripathy D, Frenkel EP, Verma UN. IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem. 2005 Oct 07; 280(40):33945-52. PMID: 16103118.
      Citations: 25     Fields:    Translation:AnimalsCells
    102. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7. PMID: 16001993.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    103. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. Qualitative research contribution to a randomized clinical trial. Res Nurs Health. 2005 Jun; 28(3):268-80. PMID: 15884025.
      Citations: 9     Fields:    Translation:Humans
    104. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. PMID: 15908529.
      Citations: 95     Fields:    Translation:Humans
    105. Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D. Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer. 2005 Apr; 6(1):45-54. PMID: 15899072.
      Citations: 24     Fields:    Translation:Humans
    106. Tripathy D. Targeted therapies in breast cancer. Breast J. 2005 Mar-Apr; 11 Suppl 1:S30-5. PMID: 15725114.
      Citations: 4     Fields:    Translation:Humans
    107. Westermann AM. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2005 Mar; 16(3):513; author reply 513. PMID: 15668265.
      Citations:    Fields:    Translation:Humans
    108. Osborne C, Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu Rev Med. 2005; 56:103-16. PMID: 15660504.
      Citations: 12     Fields:    Translation:Humans
    109. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004 Dec 15; 10(24):8152-62. PMID: 15623589.
      Citations: 364     Fields:    Translation:HumansCells
    110. Tripathy D, Body JJ, Bergstr?m B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther. 2004 Dec; 26(12):1947-59. PMID: 15823760.
      Citations: 6     Fields:    Translation:Humans
    111. Kim JE, Dodd M, West C, Paul S, Facione N, Schumacher K, Tripathy D, Koo P, Miaskowski C. The PRO-SELF pain control program improves patients' knowledge of cancer pain management. Oncol Nurs Forum. 2004 Nov 16; 31(6):1137-43. PMID: 15547636.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    112. Utkan G, B?y?k?elik A, Yal?yn B. The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. Ann Oncol. 2004 Oct; 15(10):1574; author reply 1574-5. PMID: 15367420.
      Citations:    Fields:    Translation:Humans
    113. Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Body JJ, Bergstr?m B. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004 Oct; 111(3):306-312. PMID: 15363874.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    114. Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2004 Oct; 5(4):293-8. PMID: 15507176.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    115. Tripathy A D, Diel I, Body JJ. Ibandronate reduces skeletal morbidity in patients with breast cancer. Semin Oncol. 2004 Oct; 31(5 Suppl 10):64-6. PMID: 15490378.
      Citations:    Fields:    Translation:Humans
    116. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC, Eastern Cooperative Oncology Group, Southwest Oncology Group, Cancer and Leukemia Group B, North Central Cancer Treatment Group. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72. PMID: 15329905.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    117. Edrington JM, Paul S, Dodd M, West C, Facione N, Tripathy D, Koo P, Schumacher K, Miaskowski C. No evidence for sex differences in the severity and treatment of cancer pain. J Pain Symptom Manage. 2004 Sep; 28(3):225-32. PMID: 15336334.
      Citations: 19     Fields:    Translation:Humans
    118. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9393-8. PMID: 15194824; PMCID: PMC438987.
      Citations: 176     Fields:    Translation:Humans
    119. Block KI, Cohen AJ, Dobs AS, Ornish D, Tripathy D. The challenges of randomized trials in integrative cancer care. Integr Cancer Ther. 2004 Jun; 3(2):112-27. PMID: 15165498.
      Citations: 1     Fields:    Translation:Humans
    120. Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, Koo P. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004 May 01; 22(9):1713-20. PMID: 15117994.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    121. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B, MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004 May; 15(5):743-50. PMID: 15111341.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    122. Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B, Body JJ. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004 Mar 22; 90(6):1133-7. PMID: 15026791; PMCID: PMC2409647.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    123. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70. PMID: 15020607.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    124. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004; 9(4):361-77. PMID: 15266090.
      Citations: 74     Fields:    Translation:Humans
    125. Tripathy D. Systemic therapy for advanced breast cancer. Breast J. 2004 Jan-Feb; 10 Suppl 1:S26-7. PMID: 14984487.
      Citations:    Fields:    Translation:Humans
    126. Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, MF 4265 Study Group, Body JJ, Bergstr?m B. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003 Sep; 14(9):1399-405. PMID: 12954579.
      Citations: 79     Fields:    Translation:HumansCTClinical Trials
    127. Tripathy D. Clinical testing of supplementation therapy in early stage breast cancer: pitfalls and opportunities. Integr Cancer Ther. 2003 Jun; 2(2):160-2. PMID: 15035905.
      Citations:    Fields:    Translation:Humans
    128. Tripathy D. Biologically targeted therapy: as good as advertized? Clin Breast Cancer. 2003 Jun; 4(2):89. PMID: 12864934.
      Citations:    Fields:    Translation:Humans
    129. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    130. West CM, Dodd MJ, Paul SM, Schumacher K, Tripathy D, Koo P, Miaskowski C. The PRO-SELF(c): Pain Control Program--an effective approach for cancer pain management. Oncol Nurs Forum. 2003 Jan-Feb; 30(1):65-73. PMID: 12515985.
      Citations: 17     Fields:    Translation:Humans
    131. Tripathy D. Multidisciplinary care for breast cancer: barriers and solutions. Breast J. 2003 Jan-Feb; 9(1):60-3. PMID: 12558678.
      Citations: 23     Fields:    Translation:Humans
    132. Cohen I, Tagliaferri M, Tripathy D. Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol. 2002 Dec; 29(6):563-74. PMID: 12516039.
      Citations: 35     Fields:    Translation:Humans
    133. Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res. 2002 Nov-Dec; 22(6C):3843-52. PMID: 12553004.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    134. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncol Nurs Forum. 2002 Oct; 29(9):1304-13. PMID: 12370700.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    135. Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer. 2002 May; 3 Suppl 1:8-11. PMID: 12057038.
      Citations: 4     Fields:    Translation:Humans
    136. Schumacher KL, Koresawa S, West C, Hawkins C, Johnson C, Wais E, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C. Putting cancer pain management regimens into practice at home. J Pain Symptom Manage. 2002 May; 23(5):369-82. PMID: 12007755.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    137. Tripathy D. Gemcitabine in breast cancer: future directions. Clin Breast Cancer. 2002 May; 3 Suppl 1:45-8. PMID: 12057046.
      Citations: 2     Fields:    Translation:Humans
    138. Schumacher KL, West C, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski CA. Pain management autobiographies and reluctance to use opioids for cancer pain management. Cancer Nurs. 2002 Apr; 25(2):125-33. PMID: 11984100.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    139. Block KI, Constantinou A, Hilakivi-Clarke L, Hughes C, Tripathy D, Tice JA. Point-counterpoint: soy intake for breast cancer patients. Integr Cancer Ther. 2002 Mar; 1(1):90-100. PMID: 14664752.
      Citations:    Fields:    Translation:Humans
    140. Miaskowski C, Mack KA, Dodd M, West C, Paul SM, Tripathy D, Koo P, Schumacher K, Facione N. Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. J Pain. 2002 Feb; 3(1):12-20. PMID: 14622849.
      Citations: 2     Fields:    
    141. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26. PMID: 11821453.
      Citations: 932     Fields:    Translation:HumansCTClinical Trials
    142. Miaskowski C, Dodd MJ, West C, Paul SM, Tripathy D, Koo P, Schumacher K. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol. 2001 Dec 01; 19(23):4275-9. PMID: 11731509.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    143. Tripathy D. Bisphosphonates in oncology: breast cancer and beyond. Semin Oncol. 2001 Aug; 28(4 Suppl 11):86-91. PMID: 11544583.
      Citations:    Fields:    Translation:Humans
    144. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59. PMID: 11456056.
      Citations: 32     Fields:    Translation:Humans
    145. Tagliaferri M, Cohen I, Tripathy D. Complementary and alternative medicine in early-stage breast cancer. Semin Oncol. 2001 Feb; 28(1):121-34. PMID: 11254871.
      Citations: 22     Fields:    Translation:Humans
    146. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42. PMID: 11694786.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    147. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Genentech H0650 study investigators. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9. PMID: 11167088.
      Citations: 18     Fields:    Translation:Humans
    148. Sepucha KR, Belkora JK, Tripathy D, Esserman LJ. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer. J Clin Oncol. 2000 Mar; 18(6):1230-8. PMID: 10715292.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    149. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48. PMID: 10561337.
      Citations: 690     Fields:    Translation:HumansCTClinical Trials
    150. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):78-83. PMID: 10482197.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    151. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71. PMID: 9704716.
      Citations: 207     Fields:    Translation:HumansCTClinical Trials
    152. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):737-44. PMID: 8622019.
      Citations: 246     Fields:    Translation:HumansCTClinical Trials
    153. Tripathy D. How long should adjuvant tamoxifen be continued? Oncology (Williston Park). 1994 Oct; 8(10):25-33; discussion 33, 37-8. PMID: 7803214.
      Citations:    Fields:    Translation:HumansAnimalsCells
    154. Tripathy D, Benz C. Growth factors and their receptors. Hematol Oncol Clin North Am. 1994 Feb; 8(1):29-50. PMID: 8150783.
      Citations: 1     Fields:    Translation:HumansAnimals
    155. Tripathy D, Henderson IC. Systemic adjuvant therapy for breast cancer. Curr Opin Oncol. 1992 Dec; 4(6):1041-9. PMID: 1457518.
      Citations: 1     Fields:    Translation:Humans
    156. Tripathy D, Benz CC. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. Cancer Treat Res. 1992; 63:15-60. PMID: 1363356.
      Citations: 8     Fields:    Translation:HumansCells
    157. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95. PMID: 8095168.
      Citations: 186     Fields:    Translation:HumansAnimalsCells
    158. Tripathy D, Coleman RA, Vidaillet HJ, Steenbergen C, Hirschhorn K, Packer DL. Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity. Ann Intern Med. 1988 Dec 15; 109(12):985-7. PMID: 3057987.
      Citations: 1     Fields:    Translation:HumansCells
    159. Antibody dependent cell-mediated cytotoxicity (adcc) of an anti-her2 antibody requires opsonization of tumor target. FASEB Journal. 10.
    160. PARP inhibitors. Oncology. 25.
    161. Strategies to evaluate the clinical potential of botanical agents for breast cancer. Breast Cancer Research and Treatment. 69:304.
    162. Traditional Chinese medicine in the treatment of breast cancer (Part two). Journal of Chinese Medicine. 49-53.
    163. Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer. Breast Diseases. 18:205-206.
    164. Traditional Chinese medicine in the treatment of breast cancer (Part one). Journal of Chinese Medicine. 40-49.
    165. Traditional Chinese medicine in the treatment of breast cancer. Journal of Chinese Medicine. 44-54.
    166. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget. 6:44623-44634.
    167. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer. Journal of Clinical Oncology. 34:2602-2609.
    168. Looking ahead to rational combinatorial therapy. Community Oncology. 9:40-41.
    169. Time to begin adjuvant chemotherapy and survival in breast cancer patients. Breast Diseases. 25:271-273.
    170. Biological therapy of breast cancer. BioDrugs. 14:221-246.
    171. Double-blind randomized 12-month soy intervention had no effects on breast MRI fibroglandular tissue density or mammographic density. Cancer Prevention Research. 8:942-951.
    172. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Annals of Surgical Oncology. 1-7.
    173. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Research and Treatment. 160:101-109.
    174. Highlights from. Clinical Breast Cancer. 7:535-536.
    175. Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial. Breast Cancer Research and Treatment. 69:303.
    176. Highlights from. Clinical Breast Cancer. 7:539-542.
    177. Medical oncology analysis. Integrative Cancer Therapies. 5:375-378.
    178. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    179. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Breast Diseases. 15:319-320.
    180. The BMC Medicine breast cancer collection. BMC Medicine. 13.
    181. Location of receipt of initial treatment and outcomes in long-term breast cancer survivors. PLoS One. 12.
    182. Erratum. Journal of Biological Chemistry. 280:38888.
    183. Adjuvant Trastuzumab. Breast Diseases. 17:120-121.
    184. RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer. Nature Communications. 7.
    185. Peer viewpoint. Journal of Supportive Oncology. 2:427-428.
    186. Oral daily ibandronate. European Journal of Cancer, Supplement. 2:17-20.
    187. HERMIONE. BMC Cancer. 16.
    188. First-line treatment with bevacizumab and paclitaxel prolongs progression-free survival in metastatic breast cancer. Clinical Breast Cancer. 6:105-107.
    189. The neoadjuvant model is still the future for drug development in breast cancer. Clinical Cancer Research. 21:2911-2915.
    190. 3-49 Adjuvant Docetaxel or Vinorelbine With or Without Trastuzumab for Breast Cancer. Breast Diseases. 17:278-280.
    191. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database of Systematic Reviews.
    192. Escalation of oncologic services at the end of life among patients with gynecologic cancer at an urban, public hospital. Journal of Oncology Practice. 11:e163-e169.
    193. Adjuvant Aromatase Inhibitors. Breast Diseases. 18:132-133.
    194. Value-Based Breast Cancer Care. Annals of Surgical Oncology. 1-6.
    195. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer.
    196. The Rabinowitz article reviewed. Oncology. 18:1270-1275.
    197. Highlights of the 2015 San Antonio Breast Cancer Symposium. Genes and Diseases. 3:110-113.
    198. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Breast Diseases. 16:15-16.
    199. Zebra hunting. Clinical Breast Cancer. 7:655.
    200. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Breast Diseases. 19:81-83.
    201. Breast cancer advocacy in clinical care. Breast Disease. 10:3-14.
    202. Making a difference in refractory breast cancer. Community Oncology. 8:17-19.
    203. FDA and avastin. Oncology. 24.
    204. Introduction. Clinical Breast Cancer. 3.
    205. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. Breast Diseases. 15:376-377.
    206. Dietary fat reduction improves relapse-free survival in postmenopausal women previously treated for early-stage breast cancer. Clinical Breast Cancer. 6:112-114.
    207. Highlights from. Clinical Breast Cancer. 8:313-321.
    208. New serum markers. Oncology. 22.
    209. Value of routine staging imaging studies for patients with stage III breast cancer. Journal of Surgical Oncology.
    210. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. Breast Diseases. 15:196-198.
    211. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Breast Diseases. 23:88-89.
    212. Complementary and alternative medicine in breast cancer. Breast Diseases. 15:368-369.
    213. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Molecular Cancer Therapeutics. 14:2687-2699.
    214. Highlights from. Clinical Breast Cancer. 7:536-538.
    215. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. Breast Diseases. 23:284-285.
    216. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Research and Treatment. 1-12.
    217. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. Journal of Cancer. 6:610-615.
    218. Complementary and alternative medicine in breast cancer. 787-796.
    219. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab. Journal of Clinical Oncology. 34:3511-3517.
    220. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. Breast Diseases. 19:80-81.
    221. Highlights from. Clinical Breast Cancer. 7:538-539.
    TRIPATHY's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (469)
    Co-Authors (101)
    Similar People (60)
    Same Department Expand Description